Funding for this research was provided by:
National Institute of General Medical Sciences (T32GM088129)
National Institute of Dental and Craniofacial Research (DE023577, F31DE026682, U01DE028233)
National Center for Advancing Translational Sciences (KL2TR001874)
Text and Data Mining valid from 2019-08-13
Received: 16 April 2019
Accepted: 31 July 2019
First Online: 13 August 2019
Ethics approval and consent to participate
: All mice were housed and treated in accordance with Institutional Animal Care and Use Committee guidelines at Baylor College of Medicine.
: Not applicable.
: RDG-C has received travel support from PerkinElmer and has consulted on an advisory board for Northwest Biotherapeutics. AGS receives support in the form of investigational drug from Advaxis for an investigator-initiated clinical trial. AGS receives funds for clinical trial development from Tessa Therapeutics in the form of grant support.